Termine
Präsentationen
Aktie
Aktueller Finanzbericht
News
Neueste
Tweets
vor 1 Woche 5 Tage
@MorphoSys
MorphoSys first antibody based on proprietary technology with US FDA
approval. More about Tremfya(TM) https://t.co/XeVwH0SfCm $MPSYF
vor 1 Woche 5 Tage
@MorphoSys
MorphoSys Licensee Janssen Has Received US FDA Approval for Tremfya(TM) (Guselkumab) https://t.co/gL4CdndtyR $MPSYF
vor 1 Monat 3 Wochen
@MorphoSys
MorphoSys starts Phase 3 Trial of MOR208 plus bendamustine vs. rituximab plus bendamustine in R/R DLBCL https://t.co/5RxNdrgxOn $MPSYF
vor 2 Monate 1 Woche
@MorphoSys
MorphoSys announces positive 1st results from phase 1 study with lanthipeptide MOR107 in healthy volunteers https://t.co/69X6HDWU9d $MPSYF
vor 2 Monate 3 Wochen
@MorphoSys
MorphoSys reports solid first quarter 2017 with further progress in proprietary and
partnered pipeline https://t.co/RpAlVytntf $MPSYF
vor 3 Monate 2 Wochen
@MorphoSys
Thank you @Labiotech for the nice interview. $MPSYF https://t.co/m1wpJQEV3I
vor 3 Monate 2 Wochen
@MorphoSys
Featured in our new Annual Report online magazine: MOR208, a potential new therapy for blood cancer in R&D https://t.co/ilqDckrVBp $MPSYF
vor 3 Monate 3 Wochen
@MorphoSys
2016 Annual Report now in full html https://t.co/LXw4IjxhPl
with interactive charts and as printed version https://t.co/u6opuwUSd4 $MPSYF
vor 4 Monate 2 Wochen
@MorphoSys
Find out about selected programs: modes of action, expert interviews and more in MorphoSys online magazine https://t.co/LXw4IjxhPl $MPSYF
vor 4 Monate 2 Wochen
@MorphoSys
MorphoSys presents strong financial results for 2016, guidance 2016 fully met, annual report available now https://t.co/5TtULZNXrW $MPSYF
Medien und Investoren
Anke Linnartz
Vice President, Head of Corporate Communications and IR
Telefon +49 89 89927 404
Fax: +49 89 89927 5404
Alexandra Goller
Senior Manager Corporate Communications and Investor Relations
Telefon +49 89 89927 404
Fax: +49 89 89927 5404
Jochen Orlowski
Associate Director Corporate Communications and Investor Relations
Telefon +49 89 89927 404
Fax: +49 89 89927 5404